Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis
- PMID: 12375314
Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis
Abstract
Objective: To study the diagnostic value of IgM rheumatoid factor (RF), IgA-RF, antibodies to cyclic citrullinated peptide (anti-CCP), and combinations of these antibodies, measured at baseline, to discriminate rheumatoid arthritis (RA) from undifferentiated polyarthritis (uPA) in patients with recent onset arthritis.
Methods: Patients with early arthritis with peripheral arthritis of 2 or more joints and symptom duration less than 3 years were clinically diagnosed as having RA or uPA by an experienced rheumatologist during the first year. Patients with bacterial, psoriatic, or crystal induced arthritis or spondyloarthropathy were excluded. Optimal cutoff values for serum IgM RF, IgA RF, and anti-CCP were deduced from receiver operating characteristics curves in order to predict the diagnosis of RA in early arthritis.
Results: A total of 379 patients (69% female, median age 57 yrs, range 17-86 yrs) were studied; 258 patients were clinically diagnosed as RA and 121 as uPA. Both IgM-RF > 40 IU/ml and anti-CCP > 50 AU/ml showed high specificity, but the sensitivity of these tests was low. In many RA patients the occurrence of IgM-RF and anti-CCP antibodies was independent. Thus the optimal criterion proved to be the combination of IgM-RF > 40 or anti-CCP > 50, which yielded sensitivity of 55.4% and specificity of 96.7%.
Conclusion: The criterion IgM-RF > 40 or anti-CCP > 50 is able to predict the diagnosis of RA in early arthritis patients with high specificity and acceptable sensitivity. Anti-CCP testing combined with IgM-RF testing has additional value over IgM-RF testing alone in patients with early undifferentiated oligo and polyarthritis.
Comment in
-
Rheumatoid factors: what do they tell us?J Rheumatol. 2002 Oct;29(10):2034-40. J Rheumatol. 2002. PMID: 12375308 Review. No abstract available.
Similar articles
-
The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.Arthritis Rheum. 2000 Jan;43(1):155-63. doi: 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. Arthritis Rheum. 2000. PMID: 10643712
-
The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis.J Rheumatol. 2003 Aug;30(8):1691-5. J Rheumatol. 2003. PMID: 12913923
-
Association of anti-cyclic citrullinated peptide antibodies, anti-citrullin antibodies, and IgM and IgA rheumatoid factors with serological parameters of disease activity in rheumatoid arthritis.Ann N Y Acad Sci. 2005 Jun;1050:295-303. doi: 10.1196/annals.1313.031. Ann N Y Acad Sci. 2005. PMID: 16014545
-
[New biomarkers for rheumatoid arthritis].Rinsho Byori. 2008 Apr;56(4):297-308. Rinsho Byori. 2008. PMID: 18516964 Review. Japanese.
-
Profiling of rheumatoid arthritis associated autoantibodies.Autoimmun Rev. 2010 Apr;9(6):431-5. doi: 10.1016/j.autrev.2009.11.017. Epub 2009 Nov 28. Autoimmun Rev. 2010. PMID: 19932198 Review.
Cited by
-
Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review.J Med Life. 2013;6(4):376-82. Epub 2013 Dec 25. J Med Life. 2013. PMID: 24701255 Free PMC article. Review.
-
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis.Ann Rheum Dis. 2005 Dec;64(12):1731-6. doi: 10.1136/ard.2005.035691. Epub 2005 May 5. Ann Rheum Dis. 2005. PMID: 15878904 Free PMC article.
-
Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis.Arthritis Rheum. 2009 Nov 15;61(11):1472-83. doi: 10.1002/art.24827. Arthritis Rheum. 2009. PMID: 19877103 Free PMC article. Review.
-
Comparison of serological markers between ACPA⁺ and ACPA⁻ of RA patients.Rheumatol Int. 2012 May;32(5):1143-6. doi: 10.1007/s00296-010-1757-y. Epub 2011 Jan 19. Rheumatol Int. 2012. PMID: 21246364
-
Will 14-3-3η Be a New Diagnostic and Prognostic Biomarker in Rheumatoid Arthritis? A Prospective Study of Its Utility in Early Diagnosis and Response to Treatment.Autoimmune Dis. 2022 Jan 4;2022:1497748. doi: 10.1155/2022/1497748. eCollection 2022. Autoimmune Dis. 2022. PMID: 35028161 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous